Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

ARMP Armata Pharmaceuticals, Inc. Common Stock
$4.35 -21.62% -1.20
Notify me if price changes either direction
Interactive Brokers Logotype

Buy ARMP stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 206.4M
Enterprise value 496.4M
Trailing PE -0.90625
Forward PE -3.5350318
PEG Ratio 0.0016510627530364
Enterprise to EBITDA -14.84
Enterprise to revenue 89.547
Price to book MRQ -0.51303044424332
Price to sales TTM 37.22894

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 5.5M
EBITDA -33448000
Diluted EPS TTM -5.29
Total Cash (MRQ) 24.0M
Current ratio (MRQ) 0.109
Operating Cash Flow (TTM) -25420000

ARMP trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent ARMP News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.